

NSERC Grant Update: Sixth Wave and York University Sign Amendment to Research Agreement

written by Igor Makarov | August 11, 2021

August 11, 2021 ([Source](#)) – **Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH)** (“**Sixth Wave**” or the “**Company**”) is pleased to announce a signed amendment to the research agreement and grant sponsored by the Natural Sciences and Engineering Research Council of Canada (“**NSERC**”) titled: Point-of-need Microfluidic Biosensor for Detecting Airborne Viruses using Molecularly Imprinted Polymers: Towards COVID-19 Virus Monitoring (the “**NSERC Project**”). The goal of the grant is to develop a portable, low-cost technology for rapid on-site air sampling and detection of aerosol and droplet-encapsulated viruses indoors and outdoors. The project is a collaboration between the Company and its partners, York University (“**York**”) and the Centre Technologique des Residus Industriels (“**CTRI**”). The project had a start date of August 1, 2020. A copy of the proposal submitted to NSERC can be found here: <https://sixthwave.com/NSERC2020.pdf>.

Work to date has focused on designing a prototype(s) of the Company’s AMIP technology to detect pathogens in airborne, water, and wastewater environments. The collaboration is part of Sixth Wave’s multi-pronged R&D approach to revolutionize virus detection by being able to test individual patients as well as monitoring entire populations through proactive measures such as pathogen detection in a variety (buildings, ships, aircraft, etc.) of air handling systems (HVAC) and municipal wastewater

treatment facilities.

The collaboration with York and CTRI has yielded new configurations and potential applications for the AMIP technology. Research conducted at York has demonstrated several of the previously disclosed potential capabilities of AMIP technology. Specifically, the integration of the technology into a variety of sensor arrays and detection mechanisms including electrochemical and fluorescent-based sensors. The work has also demonstrated the ability to detect a variety of pathogens, including viruses and bacteria. Although seemingly of similar origin, viruses and bacteria have drastically different technical challenges such as the different sizes and length scales of viruses vs. bacteria. The ability to develop the platform for different pathogens is a major milestone for SIXW. The imprinting and selective detection of multiple viruses and bacteria validate the claims of platform flexibility.

Microfluid devices or lab-on-a-chip devices are promising platforms to achieve rapid and sensitive immunological detection of pathogenic microorganisms such as bacteria and viruses. Inside these sub-microliter reactors, sample and reagent consumption can be significantly reduced, and the reaction time for target immobilization and identification can be shortened from hours to minutes or less.

*“The signed amendment to the research agreement provides the Company a significant opportunity regarding various pathways to commercialization of our unique Accelerated Molecular Imprinted Polymers (“**AMIPs**™”) technology,”* states Sherman McGill, Executive Vice-President and Chief Development Officer for Sixth Wave. Further, *“We greatly value our collaborative relationship with York University and their confidence in Sixth Wave as evidenced by the amendment.”*

The Company's AMIPs technology allows for novel product configuration not possible with traditional testing techniques. As a result, AMIPs has greater stability and significantly less susceptibility to environmental variables such as heat, light, and other factors which may impact traditional testing methods.

Sixth Wave is using its expertise in MIP technology to bring innovative products to market and address the insufficiencies of current technologies exposed by the COVID-19 global pandemic.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

About Sixth Wave

Sixth Wave is a development stage nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Accelerated Molecularly Imprinted Polymers (AMIPs). The Company is in the process of commercializing its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our website at: www.sixthwave.com

ON BEHALF OF THE BOARD OF DIRECTORS

"Jon Gluckman"

Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:

Phone: (801) 582-0559

E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding the planned features, capacity, and performance of the AMIPs technology and the planned Air Monitoring System. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs technology are subject to the risk that the AMIPs technology may not prove to be successful in detecting virus targets effectively or at all, the uncertainty of medical product development, the uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company

has not yet completed the development of a prototype for the product that is subject to its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.